MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency

Tumor Biology

Volumn 34, Issue 6, 2013, Pages 3945-3958

  Ren, Jie ^a   Jin, Feng ^a   Yu, Zhaojin ^a   Zhao, Lin ^a   Wang, Lin ^a   Bai, Xuefeng ^a   Zhao, Haishan ^a   Yao, Weifan ^a   Mi, Xiaoyi ^a   Wang, Enhua ^a   Olopade, Olufunmilayo I ^b   Wei, Minjie ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

BRCA1; Breast cancer; Chinese women; DNA methylation; Fluorescence in situ hybridization; MYC; Prognosis

Indexed keywords

BRCA1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MYC PROTEIN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER;

ADULT; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA METHYLATION; FEMALE; GENE DELETION; GENE DOSAGE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MIDDLE AGED; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DEPLETION; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR SUPPRESSOR GENE;

EID: 84891484479     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0983-9     Document Type: Article

References (40)

1. Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378:1461-84.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
3. Knudson Jr AG. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res. 1985;45:1437-43.
4. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66-71.
5. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet. 1995;9:444-50.
6. Rakha EA, El-Sheikh SE, Kandil MA, El-Sayed ME, Green AR, Ellis IO. Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum Pathol. 2008;39:857-65.
7. Dapic V, Monteiro AN. Functional implications of BRCA1 for early detection, prevention, and treatment of breast cancer. Crit Rev Eukaryot Gene Expr. 2006;16:233-52.
8. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000;92:564-9.
9. Catteau A, Morris JR. BRCA1 methylation: a significant role in tumour development? Semin Cancer Biol. 2002;12:359-71.
10. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008;26:4282-8.
11. Smith KL, Isaacs C. BRCA mutation testing in determining breast cancer therapy. Cancer J. 2011;17:492-9.
12. Alvarez S, Diaz-Uriarte R, Osorio A, Barroso A, Melchor L, Paz MF, et al. A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation. Clin Cancer Res. 2005;11:1146-53.
13. Perez-Valles A, Martorell-Cebollada M, Nogueira-Vazquez E, Garcia-Garcia JA, Fuster-Diana E. The usefulness of antibodies to the BRCA1 protein in detecting the mutated BRCA1 gene. An immunohistochemical study. J Clin Pathol. 2001;54:476-80.
14. Wilson CA, Ramos L, Villasenor MR, Anders KH, Press MF, Clarke K, et al. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet. 1999;21:236-40.
15. Leake R, Barnes D, Pinder S, Ellis I, Anderson L, Anderson T, et al. Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC. J Clin Pathol. 2000;53:634-5.
16. Naidu R, Wahab NA, Yadav M, Kutty MK. Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction. Int J Mol Med. 2002;9:189-96.
17. Bast Jr RC, Ravdin P, Hayes DF, Bates S, Fritsche Jr H, Jessup JM, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1865-78.
18. Russo J, Yang X, Hu YF, Bove BA, Huang Y, Silva ID, et al. Biological and molecular basis of human breast cancer. Front Biosci. 1998;3:D944-60.
19. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821-6.
20. Grunau C, Clark SJ, Rosenthal A. Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Res. 2001;29:E65-5.
21. Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, et al. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res. 2005;65:10692-9.
22. Grushko T, Ridderstrale K, Olopade O, editors. Fluorescence in situ hybridization of BRCA1 gene in breast carcinoma. Handbook of immunohistochemistry and in situ hybridization of human carcinomas. San Diego: Elsevier Academic Press; 2004
23. Pinkel D, Landegent J, Collins C, Fuscoe J, Segraves R, Lucas J, et al. Fluorescence in situ hybridization with human chromosome-specific libraries: detection of trisomy 21 and translocations of chromosome 4. Proc Natl Acad Sci U S A. 1988;85:9138-42.
24. Adachi PL, Camparoto ML, Sakamoto-Hojo ET, Brassesco MS, Peres LC. Fluorescent in situ hybridization in liver cell touch preparations from autopsy. Pathol Res Pract. 2005;201:41-7.
25. Kato H, Arakawa A, Suzumori K, Kataoka N, Young SR. FISH analysis of BRCA1 copy number in paraffin-embedded ovarian cancer tissue samples. Exp Mol Pathol. 2004;76:138-42.
26. Staff S, Nupponen NN, Borg A, Isola JJ, Tanner MM. Multiple copies of mutant BRCA1 and BRCA2 alleles in breast tumors from germ-line mutation carriers. Gene Chromosome Cancer. 2000;28:432-42.
27. Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res. 2006;8:R38.
28. Yang Q, Sakurai T, Mori I, Yoshimura G, Nakamura M, Nakamura Y, et al. Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas. Cancer. 2001;92:54-60.
29. Thangaraju M, Kaufmann SH, Couch FJ. BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines. J Biol Chem. 2000;275:33487-96.
30. Galizia E, Giorgetti G, Piccinini G, Santinelli A, Loretelli C, Bianchi F, et al. BRCA1 expression in triple negative sporadic breast cancers. Anal Quant Cytol Histol. 2010;32:24-9.
31. Miyamoto K, Fukutomi T, Asada K, Wakazono K, Tsuda H, Asahara T, et al. Promoter hypermethylation and post-transcriptional mechanisms for reduced BRCA1 immunoreactivity in sporadic human breast cancers. Jpn J Clin Oncol. 2002;32:79-84.
32. Matros E, Wang ZC, Lodeiro G, Miron A, Iglehart JD, Richardson AL. BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat. 2005;91:179-86.
33. Karray-Chouayekh S, Trifa F, Khabir A, Boujelbane N, Sellami-Boudawara T, Daoud J, et al. Clinical significance of epigenetic inactivation of hMLH1 and BRCA1 in Tunisian patients with invasive breast carcinoma. J Biomed Biotechnol. 2009;2009:369129.
34. Singh AK, Pandey A, Tewari M, Shukla HS, Pandey HP. Epigenetic silencing of BRCA1 gene associated with demographic and pathologic factors in sporadic breast cancer: a study of an Indian population. Eur J Cancer Prev. 2011;20:478-83.
35. Xu X, Gammon MD, Zhang Y, Bestor TH, Zeisel SH, Wetmur JG, et al. BRCA1 promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat. 2009;115:397-404.
36. Chen Y, Zhou J, Xu Y, Li Z, Wen X, Yao L, et al. BRCA1 promoter methylation associated with poor survival in Chinese patients with sporadic breast cancer. Cancer Sci. 2009;100:1663-7.
37. Lips EH, Mulder L, Oonk A, van der Kolk LE, Hogervorst FB, Imholz AL, et al. Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers. Br J Cancer 2013;108:2172-7
38. Wang Q, Zhang H, Kajino K, Greene MI. BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells. Oncogene. 1998;17:1939-48.
39. Li H, Lee TH, Avraham H. A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer. J Biol Chem. 2002;277:20965-73.
40. Kennedy RD, Gorski JJ, Quinn JE, Stewart GE, James CR, Moore S, et al. BRCA1 and c-Myc associate to transcriptionally repress psoriasin, a DNA damage-inducible gene. Cancer Res. 2005;65:10265-72.